Multi-year alliance leveraging Variant Bio’s AI-powered Inference platform to discover novel drug targets for kidney disease
Variant Bio, a genomics-driven AI drug discovery company, announced a multi-year research collaboration and license agreement with Boehringer Ingelheim. The partnership will focus on the discovery and validation of novel targets for cardiorenal and kidney disease, leveraging Variant Bio’s AI-powered Inference platform, which integrates proprietary genomic, deep phenotyping, and multi-omic data from studies with global populations.
Health Technology Insights: The Guthrie Clinic Announces New Chief Digital Officer
Kidney diseases are among the most urgent health challenges, affecting more than 850 million people worldwide and placing a major burden on healthcare systems. By uniting the power of AI-driven discovery with Boehringer Ingelheim’s legacy of innovation, this collaboration is set to accelerate the discovery of transformative therapies – turning genetic insights into real-world impact for millions of people living with kidney disease.
Health Technology Insights: HealthLynked Teams Up with PBACO for Payer Integration
“This strategic partnership with Boehringer Ingelheim marks another key milestone for Variant Bio and demonstrates the power of our Inference platform,” said Andrew Farnum, CEO of Variant Bio. “Combining our AI-driven discovery engine and unique data resources with Boehringer Ingelheim’s unparalleled expertise in cardiovascular and renal conditions gives us an exceptional opportunity to make a real difference for patients with kidney disease.”
“We look forward to working with Variant’s scientists and harnessing their unique platform,” said Søren Tullin, Global Head of Cardiovascular-Renal-Metabolic Diseases Research at Boehringer Ingelheim. “Discovering novel, genetically validated targets is pivotal to developing next–generation, first–in–class treatments that can transform the lives of people with kidney disease.”
Variant Bio’s Inference platform uses LLM technology, machine learning, and advanced statistical genetics to analyze hundreds of billions of data points, moving from genetic association to validated therapeutic hypotheses in a fraction of the time of traditional methods.
Under the terms of the agreement, Variant Bio will receive an upfront payment and is eligible for potential license and milestone payments totaling over $120 million.
Health Technology Insights: CooperCompanies appoints Walter Rosebrough Jr to board
To participate in our interviews, please write to our HealthTech Media Room at info@intentamplify.com
Source- PR Newswire
